Sun Pharma's $13B Organon bid signals a critical shift for Indian pharma

Sun Pharma's $13B Organon bid signals a critical shift for Indian pharma. It's less about asset acquisition, more about securing specialized portfolios and direct market access in developed economies. This move up the value chain means competing globally on brands and innovation, beyond generics. Expect other Indian majors to follow this global scale strategy.

https://pharma.economictimes.indiatimes.com/news/mergers-and-acquisitions/sun-pharma-looks-to-outshine-rival-bids-with-13-billion-organon-offer/130481341